Structure Stock Soars as Oral GLP-1 Generates ‘Highly Competitive’ Weight Loss

Structure’s aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech’s stock up nearly 103% as markets closed on Monday.